logo
Plus   Neg
Share
Email

Proteostasis Therapeutics Inc. (PTI) Jumped On FDA Designation

Proteostasis Therapeutics Inc. (PTI) announced after the bell Monday that it has been granted Breakthrough Therapy Designation from the FDA for its cystic fibrosis transmembrane conductance regulator amplifier, PTI-428.

Proteostasis Therapeutics gapped open sharply higher Tuesday, but traded in a range for the majority of the day. Shares finished with a gain of 2.24 at $6.38 on the highest volume of the year. The stock leaped to over a 2-month high.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT